R. Warner

发表

Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase.

S. Ng, D. Augeri, P. Kovar, 1999, Bioorganic & medicinal chemistry letters.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Wang Shen, Mary K Joseph, Saul H Rosenberg, 2006, Cancer research.

Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.

S. Ng, P. Kovar, S. Rosenberg, 2000, European journal of cancer.

Potent inhibitors of protein farnesyltransferase: heteroarenes as cysteine replacements.

S. Ng, P. Kovar, S. Rosenberg, 1999, Bioorganic & medicinal chemistry letters.

Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative.

S. Ng, S. Rosenberg, S. L. Gwaltney, 2003, Molecular cancer therapeutics.

Novel sulfonate derivatives: potent antimitotic agents.

S. Ng, P. Kovar, S. L. Gwaltney, 2001, Bioorganic & medicinal chemistry letters.

Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.

J. Debernardis, M. Brune, R. Warner, 1992, Journal of autonomic pharmacology.

Characterization of antihypertensive activity of ABBOTT-81988, a nonpeptide angiotensin II antagonist in the renal hypertensive rat.

D. Kerkman, J. Debernardis, M. Winn, 1994, The Journal of pharmacology and experimental therapeutics.

Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.

S. Ng, P. Kovar, S. Rosenberg, 2002, Bioorganic & medicinal chemistry letters.

Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.

S. Rosenberg, R. B. Credo, H. Sham, 2002, Journal of medicinal chemistry.

Calcium-induced vasocontractions after alpha-2 adrenergic receptor activation in the dog saphenous vein: comparison to calcium-induced contractions after potassium-depolarization.

J. Debernardis, M. Brune, J Y Lee, 1990, General pharmacology.

Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.

S. Ng, P. Kovar, S. L. Gwaltney, 2001, Bioorganic & medicinal chemistry letters.

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

C. Tse, S. Fesik, S. Ng, 2007, Cancer research.

Cardiovascular Activity of A-74283, a 5-Hydroxytryptamine1A Agent, in the Spontaneously Hypertensive Rat

J. Debernardis, A. Hancock, M. Brune, 1998, Pharmacology.

Endothelin ETA receptor antagonist reduces myocardial infarction induced by coronary artery occlusion and reperfusion in the rat.

R. Warner, T. Opgenorth, A. Adler, 1994, Pharmacology.

Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.

S. Ng, P. Kovar, S. Rosenberg, 1999, Journal of medicinal chemistry.

Preclinical pharmacological actions of (+/-)-(1'R*,3R*)-3-phenyl-1- [1',2',3',4'-tetrahydro-5',6'-methylene-dioxy-1'-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepi

D. Kerkman, A. Hancock, D. Stanisic, 1995, The Journal of pharmacology and experimental therapeutics.

Receptor interactions of Abbott-81988, a highly potent, non-peptide angiotensin-II antagonist selective for type-1 receptors.

A. Hancock, M. Winn, M. Brune, 1994, Journal of receptor research.

Discovery of a novel class of orally active, non-peptide angiotensin II antagonists.

D. Kerkman, J. Debernardis, A. Hancock, 1992, Journal of medicinal chemistry.